Vadodara: Alembic Pharmaceuticals Limited has announced that the US Food & Drug Administration (USFDA) has given final ...

Alembic Pharmaceuticals receives FDA approval for Ticagrelor Tablets 60 mg and 90 mg, therapeutically equivalent to Brilinta.

Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ticagrelor Tablets, ...

Alembic Pharmaceuticals announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ticagrelor Tablets, 90 mg, and ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2025 investor letter. A ...

Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ticagrelor Tablets, 90 mg and tentative ...

Auryxia net product revenues were $43.8 million in the first quarter of 2025 as compared to $31.0 million in the first ...

Baron Health Care Fund declined 2.54% in Q1 2025. What were the top net purchases and sales? Click here to find out.

Discover the warning signs of circulatory problems, from buttock pain to slow-healing wounds, plus the foods and activities ...

Within a few minutes after its onset, intense pain of acute myocardial infarction was abolished by briefly spraying the precordium with ethyl chloride. Prompt relief of pain did not prevent tissue ...

ISR, in stent restenosis; ST, stent thrombosis. This file was partly created using ... outcome following DCB use in acute coronary syndromes (ACS) compares with DES implantation. The use of patient ...